Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-13Rα2-targeted UCAR-T cell injection
- Development stage
- Unknown
- Lead developer
- The Second Affiliated Hospital of Soochow University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
IL-13Rα2-targeted UCAR-T cell injection is an investigational universal chimeric antigen receptor T-cell (UCAR-T) therapy being developed by the Second Affiliated Hospital of Soochow University for the treatment of advanced gliomas, including relapsed or refractory high-grade glioma. Unlike traditional autologous CAR-T therapies, UCAR-T cells are derived from healthy donors and engineered to be off-the-shelf, typically involving gene editing to reduce the risk of graft-versus-host disease (GvHD) and immune rejection. This specific candidate targets Interleukin-13 receptor subunit alpha-2 (IL-13Rα2), a tumor-associated antigen frequently overexpressed in glioblastoma multiforme (GBM) but with limited expression in normal brain tissue. The therapy is currently being evaluated in early-phase clinical trials in China to assess safety, tolerability, and preliminary efficacy.
- Other names
- IL-13Rα2 UCAR-TIL-13Rα2-targeted universal CAR-T cell injection
02
Targets
IL13RA2 (Interleukin-13 receptor subunit alpha 2)
Beyond the preview
Go deeper on IL-13Rα2-targeted UCAR-T cell injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-13Rα2-targeted UCAR-T cell injection.